20 years of revenue, earnings, cash-flow and balance-sheet history from public filings.
Edgewise Therapeutics Inc (EWTX) operates in the BIOTECHNOLOGY industry and is headquartered in Boulder, United States with about 127 employees. Its market capitalization is roughly $5 billion. In the fiscal year ended 2025-12-31, EWTX reported $0M in revenue and ($168M) in net income.
Edgewise Therapeutics, Inc., a biopharmaceutical company, discovers, develops, and commercializes therapies for the treatment of muscle disorders.
Interactive charts & full statements →
| Income statement | TTM → 2026-06-30 | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 |
|---|---|---|---|---|---|---|---|---|
| Total Revenue | $0M | $0M | $0M | $0M | $0M | $0M | $0M | $0M |
| Gross Profit | — | ($2M) | ($2M) | ($2M) | ($1M) | $0M | $0M | $0M |
| Gross Margin % | — | — | — | — | — | — | — | — |
| Operating Income (EBIT) | ($219M) | ($191M) | ($159M) | ($114M) | ($22M) | ($43M) | ($17M) | ($10M) |
| Operating Margin % | — | — | — | — | — | — | — | — |
| Net Income | ($197M) | ($168M) | ($134M) | ($100M) | ($15M) | ($42M) | ($17M) | ($9M) |
| Net Margin % | — | — | — | — | — | — | — | — |
| EBITDA | ($197M) | ($166M) | ($132M) | ($98M) | ($22M) | ($43M) | ($17M) | ($10M) |
| Earnings Per Share (EPS) | $-1.86 | $-1.63 | $-1.45 | $-1.57 | $-0.29 | $-0.85 | $-0.35 | $-0.19 |
| Shares Outstanding (M) | 108M | 103M | 92M | 64M | 54M | 50M | 49M | 49M |
USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).
| Quarterly income statement | 2026-06-30 | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 | 2025-03-31 | 2024-12-31 | 2024-09-30 |
|---|---|---|---|---|---|---|---|---|
| Total Revenue | $0M | $0M | $0M | $0M | $0M | $0M | $2M | $0M |
| Gross Profit | — | ($1M) | — | — | ($1M) | ($1M) | $1M | ($2M) |
| Gross Margin % | — | — | — | — | — | — | 50.0% | — |
| Operating Income (EBIT) | ($62M) | ($54M) | ($56M) | ($47M) | ($43M) | ($46M) | ($46M) | ($40M) |
| Operating Margin % | — | — | — | — | — | — | -2150.1% | — |
| Net Income | ($57M) | ($49M) | ($50M) | ($41M) | ($36M) | ($41M) | ($40M) | ($34M) |
| Net Margin % | — | — | — | — | — | — | -1872.6% | — |
| EBITDA | ($57M) | ($48M) | ($52M) | ($40M) | ($36M) | ($40M) | ($39M) | ($34M) |
| Earnings Per Share (EPS) | $-0.53 | $-0.46 | $-0.49 | $-0.39 | $-0.34 | $-0.43 | $-0.43 | $-0.36 |
| Shares Outstanding (M) | 108M | 107M | 103M | 105M | 105M | 95M | 92M | 94M |
USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).
| Cash flow | TTM → 2026-06-30 | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 |
|---|---|---|---|---|---|---|---|---|
| Cash from Operations (CFO) | ($159M) | ($144M) | ($109M) | ($92M) | ($53M) | ($34M) | ($15M) | ($9M) |
| Capital Expenditures (CapEx) | $1M | $0M | $1M | $6M | $6M | $1M | $0M | $0M |
| Free Cash Flow (FCF) | ($160M) | ($144M) | ($110M) | ($98M) | ($58M) | ($34M) | ($15M) | ($9M) |
| FCF Margin % | — | — | — | — | — | — | — | — |
USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).
| Quarterly cash flow | 2026-06-30 | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 | 2025-03-31 | 2024-12-31 | 2024-09-30 |
|---|---|---|---|---|---|---|---|---|
| Cash from Operations (CFO) | ($44M) | ($43M) | ($39M) | ($35M) | ($33M) | ($38M) | ($27M) | ($27M) |
| Capital Expenditures (CapEx) | $0M | $0M | $0M | $0M | $0M | $0M | $0M | $1M |
| Free Cash Flow (FCF) | ($44M) | ($43M) | ($39M) | ($35M) | ($33M) | ($38M) | ($27M) | ($28M) |
| FCF Margin % | — | — | — | — | — | — | -1285.7% | — |
USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).
| Balance sheet | 2026-06-30 | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 |
|---|---|---|---|---|---|---|---|---|
| Total Assets | $480M | $553M | $487M | $340M | $367M | $285M | $131M | $25M |
| Cash & Cash Equivalents | $72M | $61M | $42M | $86M | $22M | $16M | $105M | $24M |
| Total Liabilities | $32M | $30M | $28M | $21M | $20M | $11M | $165M | $41M |
| Total Debt (Short + Long-Term) | $1M | $1M | $1M | $1M | $1M | $0M | $0M | $0M |
| Total Shareholders' Equity | $448M | $522M | $459M | $319M | $347M | $274M | ($33M) | ($17M) |
USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).
Quarterly statements, profitability ratios, price history, insider activity and institutional holders are in the interactive EWTX viewer.
About TickerBase · Data methodology & sources · Privacy · Terms